After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Eisai has argued that maintenance dosing with Leqembi will prolong treatment benefits by targeting protofibrils, a toxic form of beta-amyloid.

Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Eisai Co (ESAIY) and Biogen Inc. (BIIB) announced that the latest findings for lecanemab-irmb, an anti-amyloid beta protofibril* antibody for the treatment of early Alzheimer’s disease, were presented ...

Biogen reported mixed third-quarter results, with EPS beating expectations despite a decline in total revenue.

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. | All told, third-quarter U.S. Leqembi sales grew 33% over the prior quarter to $39 ...

Biogen stock dipped Wednesday despite an unexpected boost from its new Alzheimer's drug, Leqembi, and an earnings guidance hike.

Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.

Biogen Inc. is now projecting a better-than-expected 2024 as the company continues to see an uptick in sales from Leqembi, ...

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company’s multiple sclerosis products.